How did GYRE's revenue and expenses shift in Q4 2024 compared to previous quarters?

Gyre Therapeutics (GYRE) exhibited a general upward trend in revenue with a significant increase in the fourth quarter of 2024, while expenses showed a more moderate increase compared to the previous three quarters:

1. **Revenue Shift**:
- GYRE's revenue increased from $27.17 million on Q1 2024 to $52.4 million on Q2 2024, and then to $77.89 million on Q3 2024 before reaching $105.76 million on Q4 2024.
- The most substantial increase occurred from Q3 to Q4, indicating a strong performance in the last months of the year.
2. **Expense Shift**:
- Expenses also increased from Q1 to Q4, but at a more gradual pace.
- The cumulative expenses were $27.17 million on Q1 2024, $52.4 million on Q2 2024, $77.89 million on Q3 2024, and $105.76 million on Q4 2024.
- The increase in expenses was more consistent throughout the year, with no significant spikes or dips.
3. **Comparison and Insights**:
- The revenue growth in Q4 2024 was more pronounced than the expense growth, suggesting an improvement in profitability for the period.
- The company's strategic focus or market conditions may have contributed to the increased revenue, which could be indicative of successful product launch, market expansion, or operational efficiency improvements.
- Monitoring the revenue and expense trends will be crucial for understanding GYRE's future financial health and potential investment opportunities.